In 2024, the trade exchange (includes international purchases and sales) of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate was US$41.6M.
In 2024, the states with the most international sales in Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were Ciudad de México (US$1.43M), Jalisco (US$522k), Estado de México (US$109k), and Baja California (US$9.86k).
The states with the most international purchases in 2024 were Ciudad de México (US$10.6M), Jalisco (US$9.98M), Baja California (US$1.75M), Estado de México (US$1.01M), and Guanajuato (US$663k).
In 2024, the main commercial destinations of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were United States (US$662k), Japan (US$452k), Colombia (US$321k), Spain (US$156k), and Peru (US$153k).
The main commercial origins of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate in 2024 were United States (US$13M), China (US$7.77M), Brazil (US$2.25M), Costa Rica (US$418k), and Spain (US$279k).
In the global context, the main exporting countries of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate in 2022 were China (US$1.28B), United States (US$831M), and France (US$751M). In the same year, the main importing countries of Glands and other Organs for Organo-Therapeutic Uses, Dried, whether or not Powdered; Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses; Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, not elsewhere Specified or Included Mate were France (US$1.14B), Singapore (US$658M), and United States (US$443M).